BC Extra | Jul 22, 2019
Clinical News

July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

ARQ-151 meets Phase IIb endpoint  Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb trial of reducing signs of plaque...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Aug 18, 2017
Financial News

Drug delivery play Intec raises $50M

On Aug. 16, Intec Pharma Ltd. (Tel Aviv; NASDAQ:NTEC) raised $50 million through the sale of 10.6 million shares at $4.70 in a follow-on underwritten by Oppenheimer, Roght Capital Partners and Maxim Group. Intec expects...
BC Extra | Aug 16, 2017
Financial News

Drug delivery play Intec raises $50M

Intec Pharma Ltd. (Tel Aviv:NTEC; NASDAQ:NTEC) jumped $0.65 (13%) to $5.50 on NASDAQ after raising $50 million through the sale of 10.6 million shares at $4.70 in a follow-on underwritten by Oppenheimer, Roth Capital Partners...
BC Week In Review | Nov 8, 2016
Clinical News

Carbidopa/levodopa GR: Ph III amended

Intec amended the ongoing, double-blind, double-dummy, U.S. Phase III Accordance Study of oral AP-CDLD to reduce enrollment to 328 patients from 460. Intec said the amendment reflects input from "key opinion leaders and biostatisticians specializing...
BC Week In Review | Apr 11, 2016
Clinical News

Carbidopa/levodopa GR: Phase III started

Intec began a double-blind, double-dummy, U.S. Phase III trial to compare oral AP-CDLD containing 50 mg carbidopa with 400 or 500 mg levodopa given twice or 3 times daily vs. Sinemet IR levodopa/carbidopa in about...
BC Extra | Aug 4, 2015
Financial News

Intec raises $30.2M in U.S. listing

Intec Pharma Ltd. (Tel Aviv:INTP; NASDAQ:NTEC) held at $6 in its first day of trading on NASDAQ after it raised $30.2 million through the sale of 5 million shares at $6 in a U.S. listing...
Items per page:
1 - 8 of 8